Company profile: BridgeBio Pharma
1.1 - Company Overview
Company description
- Provider of precision medicines for genetic diseases and cancers, developing assets including BBP-398 (SHP2 inhibitor for MAPK/RAS-driven cancers), BBP-631 (AAV5 gene therapy for congenital adrenal hyperplasia), BBP-818 (AAV gene therapy for classic galactosemia), BBP-589 (recombinant collagen 7 for dystrophic epidermolysis bullosa), BBP-681 (topical PI3KA inhibitor), and BBP-711 (GO inhibitor).
Products and services
- BBP-589: Phase 2-completed recombinant collagen 7 for dystrophic epidermolysis bullosa, engineered for treatment of DEB
- Completed Phase 2 trials underline advancement
- BBP-398: Clinical-stage SHP2 inhibitor targeting MAPK/RAS driven cancers, developed to address tumors with MAPK/RAS pathway activation
- Currently in clinical development for oncology indications
- BBP-631: Phase 1/2 clinical AAV5 gene therapy for congenital adrenal hyperplasia, architected to deliver AAV5-mediated treatment for CAH
- Undergoing Phase 1/2 clinical trials.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BridgeBio Pharma
CosmosID
HQ: United States
Website
- Description: Provider of metagenomics and bioinformatics services for rapid identification of microorganisms in various samples, offering strain-level analysis via proprietary pipeline and database to detect bacteria, viruses, fungi, and more. Provides sequencing services (amplicon, shallow/deep shotgun, bacterial isolate) and CosmosID-HUB Microbiome, an online platform with pipelines for amplicon and shotgun data, plus targeted tests and whole genome analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CosmosID company profile →
Neogen
HQ: United States
Website
- Description: Provider of food and animal safety products, developing, manufacturing and marketing a diverse line dedicated to food and animal safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogen company profile →
CTI BioPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer treatment, focused on blood-related cancers. Develops, acquires, and commercializes therapies including Pixantrone (Phase III; non-Hodgkin's lymphoma), Brostallicin (first-line Phase II; sarcoma), and OPAXIO chemotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI BioPharma company profile →
BioIVT
HQ: United States
Website
- Description: Provider of biological and in vitro products and services for biopharmaceutical, diagnostic, and biotechnology organizations. Offerings include in vivo ADME/PK studies, bioanalytical services, biospecimen characterization, consulting for drug R&D, long-term hepatocyte culture systems (HEPATOPAC and HEPATOMUNE), and Human AB Serum for cell culture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioIVT company profile →
Applied DNA Sciences
HQ: United States
Website
- Description: Provider of botanical DNA-based anti-counterfeiting, product authentication, and genetic testing solutions, offering Linea DNA for rapid, cell-free production of high-fidelity DNA for nucleic acid therapies; CertainT and SigNature DNA for supply chain source and authenticity verification; ADCL PCR-based virology testing; and TR8 pharmacogenomic testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied DNA Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BridgeBio Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BridgeBio Pharma
2.2 - Growth funds investing in similar companies to BridgeBio Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BridgeBio Pharma
4.2 - Public trading comparable groups for BridgeBio Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →